Mexico And Brazil Release Biosimilars Guidelines, But Not All Issues Resolved
This article was originally published in PharmAsia News
Mexico published its final biosimilars guidelines the same day as India, both drawing from WHO standards.
You may also be interested in...
Korea's Celltrion SVP Kim Hyoung-Ki On Gearing Up To Launch Biosimilars In Global Markets: An Interview With PharmAsia News
Up until a few years ago, South Korea's biosimilar front-runner Celltrion Inc.'s main business was manufacturing products for others. But the company inked a deal with U.S.-based Hospira in 2009 to collaborate on manufacturing and marketing eight biosimilars. Celltrion has hinted that a bigger deal with Hospira could be in the works, which would provide the Korean company with a global sales network.
Novartis's generic subsidiary Sandoz launched recombinant human growth hormone somatropin in Japan. Approved in June with the same indications as Pfizer's Genotropin (somatropin), Sandoz's somatropin marks the first biosimilar launch and the company looks to further generic launches in Japan
BEIJING - Flush with cash from expanding earnings, leading Chinese biotech outfit 3SBio is scanning the globe for promising in-licensing deals to complement its in-house drug development pipeline and is exploring the potential to one day enter the biosimilars markets in the United States and the European Union